Nicotine decreases the activity of glutamate transporter type 3

Toxicology Letters

Volumn 225, Issue 1, 2014, Pages 147-152

  Yoon, Hea Jo ^a   Lim, Young Jin ^b   Zuo, Zhiyi ^c   Hur, Wonseok ^d   Do, Sang Hwan ^e  

^a Catholic Kwandong University   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^d Korea University College of Medicine   (South Korea)

^e Seoul National University Bundang Hospital   (South Korea)

Author keywords

Excitatory amino acid transporter 3; Glutamate plasma membrane transport protein; Nicotine; Phosphatidylinositol 3 kinase; Protein kinase C; Xenopus laevis

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CALPHOSTIN C; CHELERYTHRINE; EXCITATORY AMINO ACID TRANSPORTER; GLUTAMIC ACID; NICOTINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; STAUROSPORINE; WORTMANNIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ELECTRODE; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION SYSTEM; NONHUMAN; OOCYTE; PRIORITY JOURNAL; SEIZURE; VOLTAGE CLAMP TECHNIQUE; XENOPUS;

EXCITATORY AMINO ACID TRANSPORTER 3; GLUTAMATE PLASMA MEMBRANE TRANSPORT PROTEIN; NICOTINE; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN KINASE C; XENOPUS LAEVIS;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME ACTIVATORS; EXCITATORY AMINO ACID TRANSPORTER 3; FEMALE; GLUTAMIC ACID; MEMBRANE POTENTIALS; NICOTINE; NICOTINIC AGONISTS; OOCYTES; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; RATS; SEIZURES; TIME FACTORS; XENOPUS LAEVIS;

EID: 84891461258     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2013.12.002     Document Type: Article

References (51)

1. Aguiar C.C., Almeida A.B., Araujo P.V., de Abreu R.N., Chaves E.M., do Vale O.C., Macedo D.S., Woods D.J., Fonteles M.M., Vasconcelos S.M. Oxidative stress and epilepsy: literature review. Oxid. Med. Cell. Longev. 2012, 2012:795259.
2. Aoyama K., Suh S.W., Hamby A.M., Liu J., Chan W.Y., Chen Y., Swanson R.A. Neuronal glutathione deficiency and age-dependent neurodegeneration in the EAAC1 deficient mouse. Nat. Neurosci. 2006, 9:119-126.
3. Beart P.M., O'Shea R.D. Transporters for l-glutamate: an update on their molecular pharmacology and pathological involvement. Br. J. Pharmacol. 2007, 150:5-17.
4. Benowitz N.L. Pharmacokinetic considerations in understanding nicotine dependence. Ciba Found. Symp. 1990, 152:186-200. (discussion 200-209).
5. Bergles D.E., Diamond J.S., Jahr C.E. Clearance of glutamate inside the synapse and beyond. Curr. Opin. Neurobiol. 1999, 9:293-298.
6. Bouilleret V., Ridoux V., Depaulis A., Marescaux C., Nehlig A., Le Gal L.S.G. Recurrent seizures and hippocampal sclerosis following intrahippocampal kainate injection in adult mice: electroencephalography, histopathology and synaptic reorganization similar to mesial temporal lobe epilepsy. Neuroscience 1999, 89:717.
7. Casado M., Bendahan A., Zafra F., Danbolt N.C., Aragon C., Gimenez C., Kanner B.I. Phosphorylation and modulation of brain glutamate transporters by protein kinase C. J. Biol. Chem. 1993, 268:27313-27317.
8. Chiodini F.C., Tassonyi E., Hulo S., Bertrand D., Muller D. Modulation of synaptic transmission by nicotine and nicotinic antagonists in hippocampus. Brain Res. Bull. 1999, 48:623-628.
9. Cohen S.L., Morley B.J., Snead O.C. An EEG analysis of convulsive activity produced by cholinergic agents. Prog. Neuropsychopharmacol. 1981, 5:383-388.
10. Crino P.B., Jin H., Shumate M.D., Robinson M.B., Coulter D.A., Brooks-Kayal A.R. Increased expression of the neuronal glutamate transporter (EAAT3/EAAC1) in hippocampal and neocortical epilepsy. Epilepsia 2002, 43:211-218.
11. Damaj M.I., Glassco W., Dukat M., Martin B.R. Pharmacological characterization of nicotine-induced seizures in mice. J. Pharmacol. Exp. Ther. 1999, 291:1284-1291.
12. Danbolt N.C. Glutamate uptake. Prog. Neurobiol. 2001, 65:1-105.
13. Davis K.E., Straff D.J., Weinstein E.A., Bannerman P.G., Correale D.M., Rothstein J.D., Robinson M.B. Multiple signaling pathways regulate cell surface expression and activity of the excitatory amino acid carrier 1 subtype of Glu transporter in C6 glioma. J. Neurosci. 1998, 18:2475-2485.
14. De Vitta A., Da Silva D.T., De Vitta F.C.F., De Conti M.H.S., Vieira L.M., Marta S.D., Gatti M.A.N., Sime S.F.A.P. Knowledge about smoking among schoolchildren. J. Hum. Growth Dev. 2013, 23:18-23.
15. Do S.H., Fang H.Y., Ham B.M., Zuo Z. The effects of lidocaine on the activity of glutamate transporter EAAT3: the role of protein kinase C and phosphatidylinositol 3-kinase. Anesth. Analg. 2002, 95:1263-1268.
16. Do S.H., Kamatchi G.L., Washington J.M., Zuo Z. Effects of volatile anesthetics on glutamate transporter, excitatory amino acid transporter type 3: the role of protein kinase C. Anesthesiology 2002, 96:1492-1497.
17. Dobelis P., Hutton S., Lu Y., Collins A.C. GABAergic systems modulate nicotinic receptor-mediated seizures in mice. J. Pharmacol. Exp. Ther. 2003, 306:1159-1166.
18. Dringen R. Metabolism and functions of glutathione in brain. Prog. Neurobiol. 2000, 62:649-671.
19. Dworetzky B.A., Bromfield E.B., Townsend M.K., Kang J.H. A prospective study of smoking, caffeine, and alcohol as risk factors for seizures or epilepsy in young adult women: data from the Nurses' Health Study II. Epilepsia 2010, 51:198-205.
20. Eilers H., Schaeffer E., Bickler P.E., Forsayeth J.R. Functional deactivation of the major neuronal nicotinic receptor caused by nicotine and a protein kinase C-dependent mechanism. Mol. Pharmacol. 1997, 52:1105-1112.
21. Ettinger S.L., Lauener R.W., Duronio V. Protein kinase C delta specifically associates with phosphatidylinositol 3-kinase following cytokine stimulation. J. Biol. Chem. 1996, 271:14514-14518.
22. Fedele E., Varnier G., Ansaldo M.A., Raiteri M. Nicotine administration stimulates the in vivo N-methyl-d-aspartate receptor/nitric oxide/cyclic GMP pathway in rat hippocampus through glutamate release. Br. J. Pharmacol. 1998, 125:1042-1048.
23. Ferrea S., Winterer G. Neuroprotective and neurotoxic effects of nicotine. Pharmacopsychiatry 2009, 42:255-265.
24. Floris V., Morocutti C., Ayala G.F. Effects of nicotine on the cortical, thalamic and hippocampal electrical activity in rabbits. J. Neuropsychiatry 1964, 5:247-251.
25. Frey R.S., Gao X., Javaid K., Siddiqui S.S., Rahman A., Malik A.B. Phosphatidylinositol 3-kinase gamma signaling through protein kinase Czeta induces NADPH oxidase-mediated oxidant generation and NF-kappaB activation in endothelial cells. J. Biol. Chem. 2006, 281:16128-16138.
26. Ghosheh O.A., Dwoskin L.P., Miller D.K., Crooks P.A. Accumulation of nicotine and its metabolites in rat brain after intermittent or continuous peripheral administration of [2'-(14)C]nicotine. Drug Metab. Dispos. 2001, 29:645-651.
27. Gonzalez M.I., Robinson M.B. Protein kinase C-dependent remodeling of glutamate transporter function. Mol. Interv. 2004, 4:48-58.
28. Guillet B.A., Velly L.J., Canolle B., Masmejean F.M., Nieoullon A.L., Pisano P. Differential regulation by protein kinases of activity and cell surface expression of glutamate transporters in neuron-enriched cultures. Neurochem. Int. 2005, 46:337-346.
29. Hollmann M.W., Fischer L.G., Byford A.M., Durieux M.E. Local anesthetic inhibition of m1 muscarinic acetylcholine signaling. Anesthesiology 2000, 93:497-509.
30. Kobau R., DiIorio C.A., Price P.H., Thurman D.J., Martin L.M., Ridings D.L., Henry T.R. Prevalence of epilepsy and health status of adults with epilepsy in Georgia and Tennessee: Behavioral Risk Factor Surveillance System, 2002. Epilepsy Behav. 2004, 5:358-366.
31. Kusano K., Miledi R., Stinnakre J. Cholinergic and catecholaminergic receptors in the Xenopus oocyte membrane. J. Physiol. 1982, 328:143-170.
32. Lavoie F.W., Harris T.M. Fatal nicotine ingestion. J. Emerg. Med. 1991, 9:133-136.
33. Lee G., Huang Y., Washington J.M., Briggs N.W., Zuo Z. Carbamazepine enhances the activity of glutamate transporter type 3 via phosphatidylinositol 3-kinase. Epilepsy Res. 2005, 66:145-153.
34. Maragakis N.J., Rothstein J.D. Glutamate transporters in neurologic disease. Arch. Neurol. 2001, 58:365-370.
35. Mathern G.W., Mendoza D., Lozada A., Pretorius J.K., Dehnes Y., Danbolt N.C., Nelson N., Leite J.P., Chimelli L., Born D.E., Sakamoto A.C., Assirati J.A., Fried I., Peacock W.J., Ojemann G.A., Adelson P.D. Hippocampal GABA and glutamate transporter immunoreactivity in patients with temporal lobe epilepsy. Neurology 1999, 52:453-472.
36. Nieoullon A., Canolle B., Masmejean F., Guillet B., Pisano P., Lortet S. The neuronal excitatory amino acid transporter EAAC1/EAAT3: does it represent a major actor at the brain excitatory synapse. J. Neurochem. 2006, 98:1007-1018.
37. Picciotto M.R., Brunzell D.H., Caldarone B.J. Effect of nicotine and nicotinic receptors on anxiety and depression. Neuroreport 2002, 13:1097-1106.
38. Rowell P.P., Li M. Dose-response relationship for nicotine-induced up-regulation of rat brain nicotinic receptors. J. Neurochem. 1997, 68:1982-1989.
39. Schneider N.G., Olmstead R.E., Franzon M.A., Lunell E. The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments. Clin. Pharmacokinet. 2001, 40:661-684.
40. Sepkuty J.P., Cohen A.S., Eccles C., Rafiq A., Behar K., Ganel R., Coulter D.A., Rothstein J.D. A neuronal glutamate transporter contributes to neurotransmitter GABA synthesis and epilepsy. J. Neurosci. 2002, 22:6372-6379.
41. Shanker G., Allen J.W., Mutkus L.A., Aschner M. The uptake of cysteine in cultured primary astrocytes and neurons. Brain Res. 2001, 902:156-163.
42. Sheldon A.L., Robinson M.B. The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention. Neurochem. Int. 2007, 51:333-355.
43. Shin H.J., Ryu J.H., Kim S.T., Zuo Z., Do S.H. Caffeine-induced inhibition of the activity of glutamate transporter type 3 expressed in Xenopus oocytes. Toxicol. Lett. 2013, 217:143-148.
44. Sims K.D., Straff D.J., Robinson M.B. Platelet-derived growth factor rapidly increases activity and cell surface expression of the EAAC1 subtype of glutamate transporter through activation of phosphatidylinositol 3-kinase. J. Biol. Chem. 2000, 275:5228-5237.
45. Smolinske S.C., Spoerke D.G., Spiller S.K., Wruk K.M., Kulig K., Rumack B.H. Cigarette and nicotine chewing gum toxicity in children. Hum. Toxicol. 1988, 7:27-31.
46. Tabima D.M., Frizzell S., Gladwin M.T. Reactive oxygen and nitrogen species in pulmonary hypertension. Free Radic. Biol. Med. 2012, 52:1970-1986.
47. Taylor R.G., Woodman G., Clarke S.W. Plasma nicotine concentration and the white blood cell count in smokers. Thorax 1986, 41:407-408.
48. Toker A., Cantley L.C. Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature 1997, 387:673-676.
49. Wieser H.G. ILAE Commission Report. Mesial temporal lobe epilepsy with hippocampal sclerosis. Epilepsia 2004, 45:695-714.
50. Yildiz D., Ercal N., Armstrong D.W. Nicotine enantiomers and oxidative stress. Toxicology 1998, 130:155-165.
51. Yildiz D., Liu Y.S., Ercal N., Armstrong D.W. Comparison of pure nicotine- and smokeless tobacco extract-induced toxicities and oxidative stress. Arch. Environ. Contam. Toxicol. 1999, 37:434-439.